Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
Information source: University of South Alabama
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Retinopathy of Prematurity; Retinal Detachment; Blindness
Intervention: ACULAR (Drug); REFRESH TEARS (Drug); placebo (Drug)
Phase: Phase 4
Status: Enrolling by invitation
Sponsored by: University of South Alabama
Official(s) and/or principal investigator(s):
Fabien G Eyal, M.D., Principal Investigator, Affiliation: University Of South Alabama, Children's & Women's Hospital
The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye
drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or
decrease its severity. In this study ACULAR will be compared to a placebo (artificial tear).
The hypothesis would be that ACULAR treatment will decrease the incidence of moderate to
severe ROP (grade II and above)by 50%.
Official title: Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Primary outcome: Efficacy of ACULAR compared to placebo in inhibiting the development of retinopahty of prematurity in a high risk very immature preterm group of infants
Each year ROP affects an estimated 14,000-16,000 premature, low birth weight infants in the
United States and thousands more worldwide, making it a leading cause of vision loss in
children. Of these cases, approximately 1500 infants will develop severe ROP that requires
surgical treatment. Despite those treatment, about 400-600 infants with severe ROP still
become legally blind each year.
ACULAR® (Ketorolac eye drop) is a member of nonsteroidal anti-inflammatory drugs (NSAIDs)
available for toipcal ocular use. ACULAR acts as prostaglandin inhibitor and as such
decrease prostaglandin E2 production. An increase in prostaglandin production has been
associated with various inflammatory eye disease. For instance ACULAR has been shown to be
effective in preventing the post cataract surgery inflammation that result in macular edema
in adults. Activation of the prostaglandin cascade has been demonstrated in animal models of
ROP. A previous non randomized study using ACULAR for ROP prevention has shown a possible
beneficial effect and no observed adverse effect. To clearly demonstrated and confirm this
finding a randomized study is thus necessary before one can advocate its use for prevention
of ROP. The medication is FDA approved in pediatrics for allergic conjunctivitis and post
surgical ocular inflammation.
Minimum age: N/A.
Maximum age: 15 Days.
- All preterm infants of gestational age less or equal to 28 weeks completed
gestational age and 10 to 15 days of postnatal age admitted to our regional NICU
Locations and Contacts
Division of Neonatology, Children's & Women's Hospital, University of South Alabama, Mobile, Alabama 36604-3391, United States
Starting date: November 2005
Last updated: March 12, 2008